Pharmaceutical giant Eli Lilly (NYSE: LLY) on Monday launched a late-stage clinical trial in long-term care facilities for its Covid-19 antibody treatment. The Phase 3 trial, dubbed BLAZE-2, is being conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), and will enroll up to 2,400 residents and staff at nursing homes […]
